

PHARMACOGENOMICS COMMUNITY PANEL


HIGHLIGHTS

- Uniform coverage of target coding and non-coding regions and hotspots
- High quality probe design to optimize on-target rate
- Customizable gene content developed with experts in Pharmacogenomics
- CYP2D6-specific analytical module
- Pharmacogenomics-specific output files with genotype status
- Star allele calling in 11 genes according to PharmVar nomenclature

Designed in collaboration with pharmacogenomics experts at RRPGX

Designing, creating, and testing a new gene panel takes considerable time and effort. The **SOPHiA GENETICS[™] Community Panel for Pharmacogenomics is a targeted, capture-based NGS panel** developed and tested in collaboration with RNPGx (Réseau Francophone de Pharmacogénétique) to minimize set-up challenges and accelerate your research. This panel covers a wide range of genes related to Pharmacogenomics¹ and is fully customizable, with the flexibility to add or remove genes to meet your unique requirements.

The analytical capabilities of the SOPHiA DDM[™] Platform enable you to gain accurate and cost-effective insights from your target regions of interest.



Panel size: 77 kb. Pipelines available for: NextSeq[®], MiSeq[®], and MiniSeq[™] Product code: CS2532ILLRGLY10

Want to know more? Contact us at: info@sophiagenetics.com

Where others see data, we see answers.

¹ Picard N, et al; French National Network of Pharmacogenetics (RNPGx). Therapie. 2017 Apr;72(2):185-192.



VKORC1



 $\Delta 0 0$